Campbell & CO Investment Adviser LLC Invests $1.60 Million in ANI Pharmaceuticals, Inc. $ANIP

Campbell & CO Investment Adviser LLC purchased a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 17,439 shares of the specialty pharmaceutical company’s stock, valued at approximately $1,597,000. Campbell & CO Investment Adviser LLC owned approximately 0.08% of ANI Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of ANIP. GAMMA Investing LLC raised its position in shares of ANI Pharmaceuticals by 9.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 126 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its position in shares of ANI Pharmaceuticals by 1.0% during the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock worth $1,267,000 after buying an additional 198 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of ANI Pharmaceuticals by 2.6% in the second quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company’s stock worth $816,000 after buying an additional 321 shares during the last quarter. Legal & General Group Plc raised its holdings in ANI Pharmaceuticals by 0.8% in the second quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company’s stock valued at $3,048,000 after acquiring an additional 351 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in ANI Pharmaceuticals by 10.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 4,368 shares of the specialty pharmaceutical company’s stock valued at $285,000 after acquiring an additional 396 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Activity

In other news, VP Meredith Cook sold 500 shares of the business’s stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00. Following the completion of the transaction, the vice president owned 74,374 shares of the company’s stock, valued at approximately $6,271,959.42. The trade was a 0.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the transaction, the director owned 25,157 shares of the company’s stock, valued at $2,041,490.55. This represents a 6.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 28,101 shares of company stock worth $2,453,063 over the last 90 days. Insiders own 11.10% of the company’s stock.

Analyst Ratings Changes

ANIP has been the subject of several recent analyst reports. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a report on Thursday, October 9th. Barclays started coverage on shares of ANI Pharmaceuticals in a research report on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $103.43.

ANI Pharmaceuticals Price Performance

ANIP opened at $84.83 on Friday. The company has a quick ratio of 2.04, a current ratio of 2.58 and a debt-to-equity ratio of 1.20. The company’s 50-day moving average price is $82.01 and its 200 day moving average price is $83.84. ANI Pharmaceuticals, Inc. has a fifty-two week low of $54.10 and a fifty-two week high of $99.50. The firm has a market cap of $1.91 billion, a price-to-earnings ratio of 52.04 and a beta of 0.51.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The company had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.ANI Pharmaceuticals’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, sell-side analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.